Cancer and inflammation: Promise for biologic therapy

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 335-351

  Demaria, Sandra ^a   Pikarsky, Eli ^b   Karin, Michael ^c   Coussens, Lisa M ^d   Chen, Yen Ching ^e   El Omar, Emad M ^f   Trinchieri, Giorgio ^g   Dubinett, Steven M ^h   Mao, Jenny T ^i,j   Szabo, Eva ^k   Krieg, Arthur ^l   Weiner, George J ^m   Fox, Bernard A ⁿ   Coukos, George ^o   Wang, Ena ^p   Abraham, Robert T ^p   Carbone, Michele ^q   Lotze, Michael T ^r  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c San Diego   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Pulmonary and Critical Care Section   (United States)

^j NM VA Healthcare System   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l Earle A Charles Research Institute ^*

^m Earle A Charles Research Institute   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o NATIONAL INSTITUTES OF HEALTH   (United States)

^p WYETH RESEARCH   (United States)

^q UNIVERSITY OF PITTSBURGH   (United States)

^r UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

more..

Author keywords

Chronic inflammation; COX2; Cytokine polymorphisms; Damage associated molecular pattern molecules (damps); Ethyl pyruvate; Hmgb1; Innate immunity; Pathogen associated molecular pattern molecules (pamps); Steroids; Tgf

Indexed keywords

ANTIINFLAMMATORY AGENT; ASBESTOS; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; CYTOKINE; DAMAGE ASSOCIATED MOLECULAR PATTERN; ETHYLPYRUVATE; INTERLEUKIN 1; MICRORNA; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROID; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BIOLOGICAL THERAPY; BONE MARROW CELL; CANCER GROWTH; CANCER PREVENTION; CELL DEATH; CELL SURVIVAL; CHRONIC INFLAMMATION; CIGARETTE SMOKING; ENVIRONMENTAL FACTOR; EOSINOPHIL; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTOXICITY; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS C; HEREDITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; MACROPHAGE; MAST CELL; METABOLIC STRESS; MONOCYTE; NEOPLASM; NONHUMAN; PANCREATITIS; PATHOGENICITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SENTINEL LYMPH NODE; SOLAR RADIATION; STOMACH CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WART VIRUS;

ADAPTIVE IMMUNITY; ADULT; ANIMALS; BIOLOGICAL THERAPY; CHILD; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS;

EID: 77954954369     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181d32e74     Document Type: Review

References (142)

1. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518-527. (Pubitemid 351655218)
2. Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006;103:10397-10402.
3. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
4. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447-458.
5. Zeh HJ, Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother. 2005;28:1-9.
6. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612.
7. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66:11238-11246.
8. Wyckoff JB, Wang Y, Lin EY, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649-2656.
9. Gyorki DE, Lindeman GJ. Macrophages, more than just scavengers: their role in breast development and cancer. ANZ J Surg. 2008;78:432-436.
10. Ohno S, Inagawa H, Dhar DK, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003;23:5015-5022.
11. Welsh TJ, Green RH, Richardson D, et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005;23:8959-8967.
12. Allavena P, Sica A, Garlanda C, et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155-161.
13. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116:2777-2790.
14. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13:5243-5248.
15. Wedemeyer J, Galli SJ. Decreased susceptibility of mast celldeficient Kit (W)/Kit (W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest. 2005;85:388-396.
16. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382-1397.
17. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000;88:2686-2692.
18. Samoszuk M, Kanakubo E, Chan JK. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer. 2005;5:121.
19. Lotfi R, Lee JJ, Lotze MT. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother. 2007;30:16-28.
20. Kerrebijn JD, Balm AJM, Knegt PP, et al. Macrophage and dendritic cells in head and neck squamous-cell carcinoma: an immunohistochemical study. Cancer Immunol Immunother. 1994;38:31-37.
21. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology. 1993;25:338-343.
22. Tsujitani S, Oka A, Kondo A, et al. Infiltration of dendritic cells into regional lymph nodes in gastric cancer. Cancer. 1995;75:1478-1483.
23. Furihata M, Ohtsuki Y, Ido E, et al. HLA-DR antigen-and S100 protein-positive dendritic cells in esophageal squamous cell carcinoma; their distribution in relation to prognosis. Virchows Archiv B Cell Pathol. 1992;61:409-414.
24. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10:7466-7474.
25. O'Donnell RK, Mick R, Feldman M, et al. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett. 2007;255:145-152.
26. Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP (+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459-1469.
27. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190:1417-1426.
28. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007;204:1037-1047.
29. Yakirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol. 2007;25:2506-2508.
30. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
31. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
32. Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935-1945.
33. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
34. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538-18543.
35. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22-32.
36. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev. 2008;222:145-154.
37. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-423.
38. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005;117:574-586.
39. Mandruzzato S, Solito S, Falisi E, et al. IL4Rα+ myeloidderived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562-6568.
40. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-85.
41. Cook LS, Goldoft M, Schwartz SM, et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161:152-155.
42. Hemminki K, Li X. Cancer risks in second-generation immigrants to Sweden. Int J Cancer. 2002;99:229-237. (Pubitemid 34309480)
43. Cohen RJ, Shannon BA, McNeal JE, et al. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol. 2005;173:1969-1974.
44. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-269.
45. van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Critical Reviews in Oncology/Hematology. 2007;61:104-139.
46. Chen YC, Giovannucci E, Lazarus R, et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005;65:11771-11778.
47. Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. 2004;64:2918-2922.
48. Cheng I, Plummer SJ, Casey G, et al. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:352-355. (Pubitemid 46383358)
49. Zheng SL, Liu W, Wiklund F, et al. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate. 2006;66:1556-1564.
50. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39:631-637.
51. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007;39:638-644.
52. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645-649.
53. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910-919.
54. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
55. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008;134:306-323.
56. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-1022.
57. El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut. 2001;48:743-747.
58. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398-402.
59. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193-1201.
60. Machado JC, Pharoah P, Sousa S, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001;121:823-829.
61. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and Interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002;94:1680-1687.
62. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1[β] induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14:408-419.
63. Beales IL, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut. 1998;42:227-234.
64. Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology. 2003;125:364-371.
65. Segal ED, Lange C, Covacci A, et al. Induction of host signal transduction pathways by Helicobacter pylori. Proc Natl Acad Sci U S A. 1997;94:7595-7599.
66. Su B, Ceponis PJ, Lebel S, et al. Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun. 2003;71:3496-3502.
67. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005;560:11-18.
68. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
69. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187-191.
70. Higgins SC, Lavelle EC, McCann C, et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol. 2003;171:3119-3127.
71. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132:905-912.
72. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.
73. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823-835.
74. Modlin IM, Kidd M, Hinoue T. Of Fibiger and fables: a cautionary tale of cockroaches and Helicobacter pylori. J Clin Gastroenterol. 2001;33:177-179.
75. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst. 2005;97:1317-1319.
76. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology. 2005;5:331-342.
77. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemiareperfusion. J Exp Med. 2005;201:1135-1134.
78. Tsung A, Hoffman RA, Izuishi K, et al. Hepatic ischemia/reperfusion injury involves functional tlr4 signaling in nonparenchymal cells. J Immunol. 2005;175:7661-7668.
79. Izuishi K, Tsung A, Jeyabalan G, et al. Cutting edge: highmobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol. 2006;176:7154-7158.
80. Popovic PJ, DeMarco R, Lotze MT, et al. High mobility group b1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol. 2006;177:8701-8707.
81. Ito N, Demarco RA, Mailliard R, et al. Cytolytic Cells Induce HMGB1 Release from Melanoma Cell Lines. J Leuk Biol. 2007;81:75-83.
82. Tsung A, Zheng N, Jeyabalan G, et al. Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemiareperfusion injury. J Leukoc Biol. 2007;81:119-128.
83. Rubartelli A, Lotze MT. Inside, outside, upside down: Damage associated molecular pattern molecules (DAMPs) and redox. Trends in Immunology. 2007;28:429-436.
84. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13:2836-2848.
85. Lotze MT, Zeh HJ, Rubartelli A, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews. 2007;220:60-81.
86. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27-42.
87. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51-64.
88. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clinical Cancer Res. 2007;13:7271-7279.
89. Cardinal J, Pan P, Dhupar R, et al. Cisplatin prevents HMGB1 release and is protective in a murine model of hepatic ischemia reperfusion injury. Hepatology. 2009;50:565-574.
90. Pan P, Cardinal J, Dhupar R, et al. Low dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J Leukoc Biol. 2009;86:625-632.
91. Lotfi R, Herzog GI, DeMarco RA, et al. Eosinophils oxidize DAMPs derived from stressed cells. J Immunology. 2009;183:5023-5031.
92. Dong Xda E, Ito N, Lotze MT, et al. HMGB1 release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. Journal of Immunotherapy. 2007;30:596-606.
93. Livesey KM, Tang D, Zeh HJ, et al. Not just nuclear proteins: 'novel' autophagy cancer treatment targets-p53 and HMGB1. Current Opinion Investigational Drugs. 2008;9:1259-1263.
94. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. J Translational Medicine. 2009;17:7-17.
95. Zeh HJ, Winikoff S, Landsittel DP, et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark. 2005;1:259-269.
96. Kazama H, Ricci JE, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspasedependent oxidation of HMGB-1. Immunity. 2008;29:21-32.
97. Herpin A, Lelong C, Favrel P. Transforming growth factor-brelated proteins: an ancestral and widespread superfamily of cytokines in metazoans. Dev Comp Immunol. 2004;28:461-485.
98. Jobling MF, Mott JD, Finnegan MT, et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-b) by reactive oxygen species. Radiat Res. 2006;166:839-848.
99. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent TGF-b1. Mol Endoc. 1996;10:1077-1083.
100. Chong H, Vodovotz Y, Cox GW, et al. Immunocytochemical localization of latent TGF-b1 activation by stimulated macrophages. J Cell Physiol. 1999;178:275-283.
101. Sappington PL, Cruz RJ, Harada T, et al. The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro. Biochemical Pharmacology. 2005;70:1579-1592.
102. Liang X, Schapiro N, Loughran P, et al. Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukocyte Biology. 2009;86:599-607.
103. Lee JJ, Lotze MT. Molecular basis of metastases, letter to the editor. NEJM. 2009;360:1679.
104. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
105. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79:123-130.
106. Bianchi ME. DAMP's, PAMP's and alamins: all we need toknow about danger. J Leukoc Biol. 2007;81:1-5.
107. Coffelt SB, Scandurro AB. Tumors sound the alarmin (s). Cancer Res. 2008;68:6482-6485.
108. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nature Immunol. 2007;8:11-13.
109. Seong SY, Matzinger P. Hydrophobilcity: an ancient damageassociated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469-478.
110. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: High mobility group Box 1 and Cancer. Clin Cancer Res. 2007;13:2836-2848.
111. Lotze MT, Tracey KJ. High-mobility group boz 1 protein (HMGB1) l Nuclear weapon in the immune arsenal. Nature Rev. 2005;5:331-342.
112. Bjorkoy G, Lamark T, Pankiv S, et al. Monitoring autophagic degradation of p62/SQSTM1. Methods in Enzymol. 2009;452:181-197.
113. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30:80-91.
114. Sonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med. 2009;13:24-38.
115. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A. 2009;106:2735-2740.
116. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60:1065-1075.
117. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A. 2009;106:5330-5335.
118. Schmidt WM, Spiel AO, Jilma B, et al. In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun. 2009;380:437-441.
119. Faraoni I, Antonetti FR, Cardone J, et al. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009. [Epub ahead of print].
120. Ploner A, Ploner C, Lukasser M, et al. Methodological obstacles in knocking down small noncoding RNAs. RNA. 2009;15:1797-1804.
121. Migliore C, Petrelli A, Ghiso E, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008;68:10128-10136. (PubMed PMID: 19074879).
122. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271-1277.
123. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278:1073-1077.
124. Szabo E. Primer: first do no harm-when is it appropriate to plan a cancer prevention clinical trial? Nature Clin Practice Oncol. 2008;5:348-356.
125. Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother. 2003;4:2193-2204.
126. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med. 1993;328:1313-1316.
127. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
128. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Eng J Med. 2003;348:891-899.
129. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Eng J Med. 2003;348:883-890. (Pubitemid 36297996)
130. Bertagnolli MM, Eagle CJ, Zauber AG, et al, APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Eng J Med. 2006;355:873-884.
131. Arber N, Eagle CJ, Spicak J, et al, PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Eng J Med. 2006;355:885-895.
132. Baron JA, Sandler RS, Bresalier RS, et al, APPROVe Trial Investigators. A Randomized trial of rofecoxib for the chemoprevention of colorectal cancer. Gastroenterology. 2006;131:1674-1682.
133. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. NEJM. 2002;346:1054-1059.
134. Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004;10:1565-1573.
135. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008;14:2095-2101.
136. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004;10:6502-6511.
137. Heath EI, Canto MI, Piantadosi S, et al, Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007;99:545-557.
138. Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled. Double-Blind Trial Cancer Prev Res. 2007;1:32-38.
139. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Eng J Med. 2007;356:2131-2142.
140. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-a2b. Clin Cancer Res. 2007;13:2422-2428.
141. Yanai H, Ban T, Wang ZC, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462:99-103. (5 November 2009) | doi:10.1038/nature08512.
142. Kang R, Tang D, Schapiro NE, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2009. [Epub ahead of print] PubMed PMID: 19834494.